Two challenges providers may face under the proposed rule.
While the jury is still out on how consumers will react to the administration’s proposed price transparency rule, there are two clear challenges that the ruling could pose for providers, according to one expert.
Under the proposed rule, hospitals would be more transparent about their charges.
“First, the proposed rule might significantly affect providers’ ability to negotiate varied rates in payer contracts,” says John Kelly, principal business advisor, Edifecs, a global health information technology solutions company based in Bellevue, Washington, with operations internationally. “Providers often do not want payers knowing the various rates they are charging and the discounts that some payers might be receiving.”
Second, this rule would require providers to publish a price list, he says.
Related: To Lower Healthcare Costs, Lower ED Visits
“However, in fee-for-service models, providers need to charge according to the chargemaster fee schedule,” Kelly says. “The reality is, hospital chargemasters are often far out of sync with the payments made under contracts to payers. Calculating a single price list that reflect reality will be a significant challenge. Patients rarely are charged the chargemaster price, so publishing the official chargemaster would be misleading and create a very negative view of a hospitals actual pricing practices.”
According to Kelly, as healthcare executives consider responding to this proposed rule, one solution might be to consider charging based on an average price of a service rather than the chargemaster price.
“Regardless, there is a clear movement toward greater cost transparency for patients, the key will be how we provide patients with the most current and accurate information rather than outdated models,” he says.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More
FDA Accepts Supplemental BLA for Bimzelx in Hidradenitis Suppurativa
April 4th 2024The FDA is also considering a separate BLA for a 2 mL syringe. Bimzelx is already available to treat plaque psoriasis as a 1 ml syringe; a dose is two subcutaneous injections with a cost of $7,200 per syringe.
Read More